Figure 4
Figure 4. Correlative studies of peripheral blood immunophenotype and ATG levels in patient 32; this patient died of CMV pneumonitis post-CTL infusion. (A) Peripheral blood immunophenotype of lysed whole blood of patient 32 pre-CTL infusion (day 31 posttransplant) and day 56 postinfusion (day 87 posttransplant). (B) Plasma ATG levels in 4 patients who received CTL infusions following conditioning containing ATG. Patient 32 () developed CMV pneumonitis and died 88 days posttransplant (57 days post-CTL infusion). Total doses of ATG administered were: patient 25, 30 mg/kg; patient 28, 15 mg/kg; patient 32, 30 mg/kg; and patient 40, 20 mg/kg.

Correlative studies of peripheral blood immunophenotype and ATG levels in patient 32; this patient died of CMV pneumonitis post-CTL infusion. (A) Peripheral blood immunophenotype of lysed whole blood of patient 32 pre-CTL infusion (day 31 posttransplant) and day 56 postinfusion (day 87 posttransplant). (B) Plasma ATG levels in 4 patients who received CTL infusions following conditioning containing ATG. Patient 32 () developed CMV pneumonitis and died 88 days posttransplant (57 days post-CTL infusion). Total doses of ATG administered were: patient 25, 30 mg/kg; patient 28, 15 mg/kg; patient 32, 30 mg/kg; and patient 40, 20 mg/kg.

Close Modal

or Create an Account

Close Modal
Close Modal